Monthly Prescribing Reference: β-Catenin Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis Please provide your email address to receive an email when new articles are posted on . For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower ... ascopubs.org: Multiple Approach to the Exploration of Genotype-Phenotype Correlations in Familial Adenomatous Polyposis Multiple Approach to the Exploration of Genotype-Phenotype Correlations in Familial Adenomatous Polyposis Nature: Exclusion of an extracolonic disease modifier locus on chromosome 1p33–36 in a large Swiss familial adenomatous polyposis kindred Exclusion of an extracolonic disease modifier locus on chromosome 1p33–36 in a large Swiss familial adenomatous polyposis kindred Identification of High-Performing Safety Net Hospitals for Radical Cystectomy: Implications for National Cancer Institute Cancer Center Partnership Familial adenomatous polyposis (FAP) is an autosomal ...
Nasdaq: Biodexa Activates First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis Biodexa Activates First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis Nature: Reply: Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients Reply: Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients Nasdaq: MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis Researchers have developed an innovative drug treatment for familial adenomatous polyposis (FAP), a rare, inherited condition that affects adolescents and young adults and often leads to colorectal ... Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...
